A big finish confirms 2019 as a takeover year to remember
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
The big cap empire strikes back
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
Relugolix gets a Hero’s welcome in prostate cancer
The Hero study gives Myovant an opportunity to change the way hormone-sensitive prostate cancer is treated.
Reata’s worsened Cardinal results could still be good enough
The pivotal portion of bardoxolone’s Cardinal study can’t match earlier data, but is still sufficient for filing.
Reata looks to outsmart Abbvie again
Fresh from buying omaveloxolone and bardoxolone rights back from Abbvie, Reata sees the first part of the puzzle fall into place.
EADV 2019 – Pfizer carves out a niche for abrocitinib
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
US pricing watchdog spotlights an old pharma trick
Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
Deal-depressed third quarter leaves nowhere to hide
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Europe and Asia provide a safe haven as US stocks falter
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.